MX2021006863A - Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer. - Google Patents

Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer.

Info

Publication number
MX2021006863A
MX2021006863A MX2021006863A MX2021006863A MX2021006863A MX 2021006863 A MX2021006863 A MX 2021006863A MX 2021006863 A MX2021006863 A MX 2021006863A MX 2021006863 A MX2021006863 A MX 2021006863A MX 2021006863 A MX2021006863 A MX 2021006863A
Authority
MX
Mexico
Prior art keywords
compositions
treating cancer
bacterial strains
parabacteroides
parabacteroides bacterial
Prior art date
Application number
MX2021006863A
Other languages
English (en)
Inventor
Imke Elisabeth MULDER
Suaad Ahmed
Parthena Fotiadou
Anna Ettorre
Original Assignee
4D Pharma Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/080131 external-priority patent/WO2020089488A1/en
Priority claimed from GBGB1916001.9A external-priority patent/GB201916001D0/en
Application filed by 4D Pharma Res Limited filed Critical 4D Pharma Res Limited
Publication of MX2021006863A publication Critical patent/MX2021006863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona una composición que comprende una cepa bacteriana del género Parabacteroides, para su uso en un método para tratar o prevenir el cáncer en un sujeto, donde el cáncer comprende la señalización de ERK oncogénica.
MX2021006863A 2018-12-12 2019-12-12 Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer. MX2021006863A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18212087 2018-12-12
PCT/EP2019/080131 WO2020089488A1 (en) 2018-11-02 2019-11-04 Compositions comprising bacterial strains
GBGB1916001.9A GB201916001D0 (en) 2019-11-04 2019-11-04 Compositions comprising bacterial strains
PCT/EP2019/084994 WO2020120717A1 (en) 2018-12-12 2019-12-12 Compositions comprising parabacteroides bacterial strains for treating cancer

Publications (1)

Publication Number Publication Date
MX2021006863A true MX2021006863A (es) 2021-09-14

Family

ID=71075994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006863A MX2021006863A (es) 2018-12-12 2019-12-12 Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer.

Country Status (15)

Country Link
US (1) US11446336B2 (es)
EP (1) EP3876964A1 (es)
JP (1) JP2022513208A (es)
KR (1) KR20210102311A (es)
CN (1) CN113207282A (es)
AU (1) AU2019396657A1 (es)
BR (1) BR112021010917A2 (es)
CA (1) CA3122347A1 (es)
EA (1) EA202191631A1 (es)
IL (1) IL283851A (es)
MA (1) MA54161A (es)
MX (1) MX2021006863A (es)
SG (1) SG11202106258YA (es)
TW (1) TW202038978A (es)
WO (1) WO2020120717A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114025794A (zh) * 2018-11-02 2022-02-08 4D制药研究有限公司 包含细菌菌株的组合物
CN113559275B (zh) * 2021-09-24 2021-12-24 广东粤港澳大湾区国家纳米科技创新研究院 一种一锅法制备高分子/康普瑞汀a4/blz945纳米键合药的方法
CN114588182B (zh) * 2021-12-28 2023-09-01 南京医科大学 植物乳杆菌l168辅助索拉非尼治疗肝癌的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20180078587A1 (en) 2015-03-18 2018-03-22 Trustees Of Tufts College Compositions and methods for preventing colorectal cancer
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
AU2017234120B2 (en) 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
EP3541400A2 (en) 2016-11-18 2019-09-25 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
WO2018112365A2 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
WO2018112363A1 (en) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Methods of treating cancer using parabacteroides
CN110191946A (zh) 2016-12-23 2019-08-30 学校法人庆应义塾 诱导cd8+t细胞的组合物及方法
BR112019028301A2 (pt) 2017-07-05 2020-07-14 Evelo Biosciences, Inc. composições e métodos para tratar câncer com o uso de bifidobacterium animalis ssp. lactis

Also Published As

Publication number Publication date
AU2019396657A1 (en) 2021-07-08
CN113207282A (zh) 2021-08-03
SG11202106258YA (en) 2021-07-29
CA3122347A1 (en) 2020-06-18
JP2022513208A (ja) 2022-02-07
TW202038978A (zh) 2020-11-01
US20210283194A1 (en) 2021-09-16
KR20210102311A (ko) 2021-08-19
BR112021010917A2 (pt) 2021-08-31
IL283851A (en) 2021-07-29
WO2020120717A1 (en) 2020-06-18
US11446336B2 (en) 2022-09-20
MA54161A (fr) 2022-03-23
EA202191631A1 (ru) 2021-09-03
EP3876964A1 (en) 2021-09-15

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2020009455A (es) Composiciones que comprenden cepas bacterianas.
NZ749872A (en) Compositions comprising bacterial strains
AU2019264537A1 (en) Beta-lactamase inhibitors
SA517390513B1 (ar) تركيبات تشتمل على سلالات بكتيرية
MX2020005772A (es) Composiciones que comprenden cepas bacterianas.
WO2020120714A8 (en) Compositions comprising bacterial strains
MX2017011630A (es) Composiciones y metodos para tratar rosacea y acne.
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
EP3750907A3 (en) Raav-based compositions and methods for treating amyotrophic lateral sclerosis
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2021006863A (es) Composiciones que comprenden cepas bacterianas de parabacteroides para tratar el cancer.
CY1125211T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MX2022007775A (es) Composición para usarse en terapia de microbiota.
MX2019010492A (es) Kits y metodos para preparar composiciones de plaquetas con patogeno inactivado.
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
MX2018004274A (es) Metodos y composiciones para contracciones musculares no deseadas o anormales.
IL281951A (en) compounds containing bacterial strains
WO2019078698A3 (ko) 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
IL280895A (en) compounds containing bacterial strains
WO2018081817A3 (en) Targeting microrna-101-3p in cancer therapy
MX2021003598A (es) Microorganismos para la inhibicion de patogenos vegetales.
MX2019009200A (es) Composiciones y métodos para inhibir el reticulón 4.
MX2021013908A (es) Tratamiento para el cáncer.
WO2018183219A3 (en) Nucleic acid-based compositions and methods for treating small vessel diseases